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In our previous modeling work, based on the experimental data of well-characterized
nucleotide-binding domains (NBDs) from ABC transporters, we have described the
heterodimeric structure of the two NBDs of human CFTR, with the two ATP-binding
sites located at the interface between the two subunits [1,2]. Only one ATP-binding
site was predicted to be enzymatically active. Our model and the concomitant
resolution of NBD1 3D structures by others also revealed that the F508 side chain
was exposed on the NBD1 surface, in a position allowing interactions with the
membrane-spanning domains (MSDs).
Here, we have considered the experimental structure of the bacterial multi-drug
transporter Sav1866 [3], to gain insight into the structure of the full length CFTR
protein. Alignment of the MSDs, which share a low level of sequence identity,
was performed using Hydrophobic Cluster Analysis, a sensitive method which had
already allowed to reﬁne the alignment of the CFTR NBD1 N-terminal region [1,2].
The NBD heterodimer build on the Sav1866 template ﬁts remarkably with that
previously constructed on MJ0796.
Our present model of an ATP-bound, outward-facing conformation of the CFTR
MSD/NBD heterodimer, is supported by mutagenesis data and highlights at the
atomic level the crucial role of speciﬁc residues: (i) residues within the MSDs
for substrate translocation and (ii) residues within the intracellular loops (ICL) for
contacts with the ATP-binding sites (ICL1/ICL3) or with the regions encompassing
F508 and its corresponding NBD2 residue (ICL2/ICL4).
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Background: Previous molecular and functional characterization of 3 novel
CBAVD-causing mutations identiﬁed in both NBDs, showed that all of them reduced
CFTR whole-cell currents. While P439S and P1290S probably reduced the number
of CFTR channels in the membrane, E1401K reduces CFTR channel function.
The aim of this work was to analyse the structural localization of the mutated
residues in order to better understand the molecular alterations introduced by these
mutations and predict their effects on protein function.
Methods: We performed an in-depth analysis of ABC transporters with known
3D structure and compared their amino acid sequences with human CFTR NBD
heterodimer.
Results: Sequence and structural alignment showed that all mutations appear to be
far from the interaction with the R domain. E1401K is located in NBD2 close to
ATP binding site and is likely to disturb ATP binding. P439S is located in NBD1
and seems to cause a structural change which impairs NBD-dimerization. P1290S
is located just before the Q-loop glutamine residue, near NBD/MSD interface and
therefore is likely to impair NBD-MSD assembly, as well as signalling with the
MSD.
Conclusion: While E1401K causes clinical disease by affecting activation of the
channel via ATP (class III), P439S and P1290S reduce the fold stability or folding
and subsequent CFTR maturation (class II). Furthermore, P1290S is likely to also
affect ion channel activation (class III). CFTR mutations here analysed lead to
limited impairment of CFTR activity, the residual function of mutant channels
although sufﬁcient to prevent CF can lead to an atypical/mild CF phenotype, such
as CBAVD.
62* CFTR missing the ﬁrst four transmembrane segments enhances
wild type and DF508 CFTR processing
L. Cebotaru1, N. Vij1, I. Ciobanu1, J. Wright1, W. Guggino1. 1School of Medicine,
Johns Hopkins University, Baltimore, MD, USA
We created an AAV vector expressing a truncated CFTR driven by a chicken beta
actin promoter (rAAV-CB-D264-CFTR). D264 CFTR is missing the ﬁrst 264 amino
acids of wt CFTR. When expressed in COS7 cells, D264 CFTR protein expression
is barely detectable. To examine why, cells were transfected with D264 CFTR and
treated for 16 hours with 10mM of proteasome inhibitors MG132 and PS341. In
cells treated with these inhibitors, D264 CFTR protein expression was signiﬁcantly
increased. Lysosomal inhibitors did not have a signiﬁcant effect. Cycloheximide
experiments showed that D264 is more rapidly degraded than DF508 CFTR. In cells
cotransfected with both wt CFTR and D264 CFTR, there was a signiﬁcant increase
in the mature C band of wt CFTR compared to cells expressing wt CFTR alone.
In cells cotransfected with both DF508 and D264 CFTR, there was a signiﬁcant
increase in the mature C band of DF508 CFTR compared to cells expressing DF508
alone. This suggests that D264 CFTR enhanced the maturation of CFTR from B to
C bands. Enhanced maturation from B band to C band also occurred when D264
CFTR was transfected into HeLa cells stably expressing DF508 CFTR and CFBE
41o- cells stably expressing DF508 CFTR. DF508 CFTR is known to associate
with VCP (valosin-containing protein) and with the cytosolic histone deacetylase,
HDAC6. We veriﬁed that D264 CFTR binds to VCP and to HDAC6 two outcomes
that are expected to enhance degradation.
In conclusion, D264 CFTR is rapidly degraded by the proteasome and lacks
biosynthetic arrest in the ER when compared to DF508 CFTR. D264 occupies
the quality control mechanism allowing more DF508 CFTR to mature. The data
suggest that D264 CFTR is a useful gene therapy vector.
Supported by: NIH and CFF.
63* The revertant mutants G550E and 4RK alter the processing
efﬁciency and gating behaviour of the CF mutant G551D
L.S. Pissarra1, Z. Xu2, C.M. Farinha1,3, D.N. Sheppard2, M.D. Amaral1,3.
1Chemistry and Biochemistry, University of Lisboa, Lisboa, Portugal; 2Physiology
and Pharmacology, University of Bristol, Bristol, United Kingdom; 3Centre of
Human Genetics, National Institute of Health, Lisboa, Portugal
G550E and 4RK (the simultaneous mutation of four arginine-framed tripeptides
(AFTs): R29K, R516K, R555K and R766K) are second site mutations that rescue
the processing and function of F508del-CFTR, the most common CF mutation.
These revertant mutations rescue F508del-CFTR from retention within the ER by
distinct mechanisms: G550E likely alters the conformation of the ﬁrst nucleotide-
binding domain (NBD1), whereas 4RK likely allows F508del-CFTR to escape ER
retention/retrieval mediated by AFTs. Both G550E and one of the AFTs, (R555)
lie close to residue G551, where the CF mutation G551D occurs, generating a
correctly localized Cl− channel with a severe gating defect. Here, we explored
how G550E and 4RK inﬂuence the processing and gating behaviour of G551D-
CFTR, using BHK cells expressing CFTR variants and biochemical and functional
assays. Western blotting revealed that the revertant mutants did not alter the
amount of mature protein produced by G551D, which was equivalent to that
of wild-type CFTR. However, pulse-chase labelling demonstrated that G550E,
but nor 4RK, enhanced slightly G551D-CFTR processing efﬁciency. By iodide
efﬂux, neither G550E nor 4RK restored function to G551D-CFTR. Of note, single-
channel recording revealed that G550E and especially 4RK attenuated markedly
the prolonged closures of G551D-CFTR. Thus, both G550E and the AFTs have
a direct effect on CFTR channel gating, raising the possibility that 4RK might
inﬂuence G551D-CFTR folding.
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